Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data
Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Takeda unveils secondary endpoint data from Phase III PsO pill trials
Takeda has released data for its plaque psoriasis (PsO) pill in key secondary endpoints in high-impact areas, supporting a route…
-
Veradermics stock jumps again on female hair loss drug win
Veradermics has seen another jump in its stock price as its hair loss drug showed benefit in women with androgenetic alopecia…
-
Smarter data, faster decisions: How biotech funding pressures are reshaping clinical development
As the biotech sector emerges from a challenging funding cycle, its effects continue to shape how companies design trials, generate…
-
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement…
-
FDA finalises psychedelic clinical trial guidance
The US Food and Drug Administration (FDA) has finalised its formal guidance for clinical trials involving psychedelic drugs. The FDA…
-
Alkermes releases nine-month data as OX2R race heats up
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in…
-
GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial
GSK’s bet on Hansoh Pharmaceutical’s antibody-drug conjugate (ADC) seems to be paying off as the drug met all its endpoints…
-
Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase…
-
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a…